Search
Lymphoma Clinical Trials in Glendale, AZ
A listing of 2 Lymphoma clinical trials in Glendale, AZ actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
1 - 2 of 2
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Lymphoma
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The city of Glendale, Arizona, currently has 2 active clinical trials seeking participants for Lymphoma research studies.
Featured Trial
Healthy Participants Needed (Colonoscopy + Cancer Screening)
Recruiting
Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
Conditions:
Healthy
Healthy Volunteers
Healthy Subjects
Healthy Volunteer
Healthy Participants
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Conditions:
Healthy
Healthy Volunteer Study
Featured Offer
Lose 20% of Body Weight With GLP-1's
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss (up to 22% of body weight).
Get $50 off your first order using promo code: policy-lab-50
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Chronic Cough Study
Recruiting
Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Allergic Asthma
Featured Trial
Buy Retatrutide Online Through Celia
Recruiting
Retatrutide (formerly M25) is an investigational peptide being studied for its potential in supporting weight management and metabolic health. It acts on GLP-1, GIP, and glucagon receptors to influence appetite, energy regulation, and fat metabolism.
Conditions:
Healthy
Featured Trial
COVID-19 Vaccine Clinical Trial (Compensation Provided)
Recruiting
Healthy adults ages 50-64 may qualify. You may be eligible if you haven’t received a COVID-19 vaccine and haven’t had COVID-19 in the last 90 days.
Qualified participants may receive compensation for time and travel.
Qualified participants may receive compensation for time and travel.
Conditions:
Healthy
Vaccine
COVID19
COVID-19
COVID-19 Vaccine
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Recruiting
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still maturing.
The goal of this study is to learn if more people who receive zilovertamab vedotin (MK-2140) and R-CHP have the cancer respond (go away) than those who receive polatuzumab vedotin and R-CHP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Palo Verde Cancer Specialists ( Site 0105), Glendale, Arizona
Conditions: Lymphoma, Large B-Cell, Diffuse
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Recruiting
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Palo Verde Hematology Oncology, Glendale, Arizona
Conditions: Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
1 - 2 of 2